Last reviewed 2026-04-20 · How we verify

Vaccine Candidate #1

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Pain
• Fatigue
• Headache
• Swelling
• Redness
• Upper respiratory tract infection
• Irritability
• Pyrexia
• Malaise
• Decreased appetite
• Somnolence
• Myalgia

Key clinical trials

• A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults (PHASE1, PHASE2)
• First-in-Human PfSPZ-LARC2 Vaccination/CHMI (PHASE1)
• A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) (PHASE2)
• A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age (PHASE1)
• Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age (PHASE1, PHASE2)
• A Study to Learn About mRNA Vaccines Against Influenza in Adults (PHASE2)
• A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus. (PHASE1)
• Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Vaccine Candidate #1 CI brief — competitive landscape report
• Vaccine Candidate #1 updates RSS · CI watch RSS
• Pfizer portfolio CI